Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
524 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01453062 | Phase IV Observational Study in Chronic Lymphocytic Leukemia | completed | — | 1 | GlaxoSmithKlineINDUSTRY | 0 | Jul 8, 2014 | clinicaltrials |
| NCT00349349 | HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab | completed | Phase 2 | 223 | GlaxoSmithKlineINDUSTRY | 0 | Jun 4, 2014 | clinicaltrials |
| NCT01077648 |
| Brain Metastasis in Breast Cancer Patients |
| completed |
| — |
| 1 |
| GlaxoSmithKlineINDUSTRY |
| 0 |
| May 26, 2014 |
| clinicaltrials |
| NCT02034097 | A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer | withdrawn | Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 0 | May 19, 2014 | clinicaltrials |
| NCT00802737 | Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL) | completed | Phase 4 | 29 | GlaxoSmithKlineINDUSTRY | 1 | May 14, 2014 | clinicaltrials |
| NCT01266967 | A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain(Break MB) | completed | Phase 2 | 172 | GlaxoSmithKlineINDUSTRY | 6 | May 8, 2014 | clinicaltrials |
| NCT01449825 | Hepatic Monitoring for Pazopanib | completed | — | 1 | GlaxoSmithKlineINDUSTRY | 0 | Apr 21, 2014 | clinicaltrials |
| NCT00920140 | Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias | completed | Phase 2 | 97 | GlaxoSmithKlineINDUSTRY | 4 | Apr 2, 2014 | clinicaltrials |
| NCT01037127 | Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor | completed | Phase 2 | 97 | GlaxoSmithKlineINDUSTRY | 2 | Mar 31, 2014 | clinicaltrials |
| NCT01772225 | NSCLC Burden of Illness Study(LuCaBIS) | completed | — | 1 | GlaxoSmithKlineINDUSTRY | 0 | Mar 31, 2014 | clinicaltrials |
| NCT00849472 | Treatment With Pazopanib for Neoadjuvant Breast Cancer | completed | Phase 2 | 101 | GlaxoSmithKlineINDUSTRY | 2 | Mar 4, 2014 | clinicaltrials |
| NCT00410163 | Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients(BIFROST) | completed | Phase 2 | 61 | GlaxoSmithKlineINDUSTRY | 2 | Feb 10, 2014 | clinicaltrials |
| NCT00997061 | SCOT Registry: Small Cell Lung Cancer Treatment and Outcome(SCOT) | completed | — | 500 | GlaxoSmithKlineINDUSTRY | 14 | Feb 3, 2014 | clinicaltrials |
| NCT00394836 | HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab | completed | Phase 2 | 116 | GlaxoSmithKlineINDUSTRY | 1 | Jan 29, 2014 | clinicaltrials |
| NCT00390806 | Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer | completed | Phase 3 | 472 | GlaxoSmithKlineINDUSTRY | 6 | Jan 20, 2014 | clinicaltrials |
| NCT00387764 | Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer | completed | Phase 3 | 80 | GlaxoSmithKlineINDUSTRY | 20 | Jan 14, 2014 | clinicaltrials |
| NCT00002767 | Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma | unknown | Phase 3 | 300 | GlaxoSmithKlineINDUSTRY | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00005865 | Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | — | GlaxoSmithKlineINDUSTRY | 3 | Jan 6, 2014 | clinicaltrials |
| NCT01195259 | Malignancy Meta Analysis for BRL49653 | completed | — | 1 | GlaxoSmithKlineINDUSTRY | 0 | Oct 28, 2013 | clinicaltrials |
| NCT01905462 | Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK | completed | — | 1,046 | GlaxoSmithKlineINDUSTRY | 1 | Sep 30, 2013 | clinicaltrials |
| NCT01231581 | Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer | completed | Phase 2 | 160 | GlaxoSmithKlineINDUSTRY | 2 | Sep 26, 2013 | clinicaltrials |
| NCT01551537 | Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka | withdrawn | — | 0 | GlaxoSmithKlineINDUSTRY | 0 | Sep 9, 2013 | clinicaltrials |
| NCT00753688 | Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy(PALETTE) | completed | Phase 3 | 369 | GlaxoSmithKlineINDUSTRY | 13 | Aug 22, 2013 | clinicaltrials |
| NCT00043927 | Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults | completed | Phase 3 | 760 | GlaxoSmithKlineINDUSTRY | 34 | Aug 21, 2013 | clinicaltrials |
| NCT00003635 | 506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents | completed | Phase 2 | — | GlaxoSmithKlineINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT01476085 | Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL) | terminated | Phase 1 | 1 | GlaxoSmithKlineINDUSTRY | 1 | Jul 1, 2013 | clinicaltrials |
| NCT00486954 | Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer | completed | Phase 3 | 273 | GlaxoSmithKlineINDUSTRY | 4 | Jun 20, 2013 | clinicaltrials |
| NCT00871403 | Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 107 | GlaxoSmithKlineINDUSTRY | 2 | Jun 20, 2013 | clinicaltrials |
| NCT01381601 | Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics) | completed | — | 1 | GlaxoSmithKlineINDUSTRY | 0 | May 13, 2013 | clinicaltrials |
| NCT01381614 | Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS) | completed | — | 1 | GlaxoSmithKlineINDUSTRY | 0 | May 13, 2013 | clinicaltrials |
| NCT01837511 | Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients | completed | — | 377 | GlaxoSmithKlineINDUSTRY | 2 | Apr 23, 2013 | clinicaltrials |
| NCT00350727 | Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma(VEG102857) | completed | Phase 2 | 75 | GlaxoSmithKlineINDUSTRY | 0 | Apr 19, 2013 | clinicaltrials |
| NCT00276276 | Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer | completed | Phase 3 | 141 | GlaxoSmithKlineINDUSTRY | 6 | Apr 15, 2013 | clinicaltrials |
| NCT01137994 | A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer | withdrawn | Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Mar 13, 2013 | clinicaltrials |
| NCT00049998 | Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer | completed | Phase 3 | 760 | GlaxoSmithKlineINDUSTRY | 31 | Mar 4, 2013 | clinicaltrials |
| NCT00558103 | Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | completed | Phase 2 | 163 | GlaxoSmithKlineINDUSTRY | 28 | Feb 4, 2013 | clinicaltrials |
| NCT01128543 | Lapatinib in Combination With Vinorelbine | completed | Phase 2 | 29 | GlaxoSmithKlineINDUSTRY | 1 | Dec 12, 2012 | clinicaltrials |
| NCT00316173 | Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer | completed | Phase 2 | 77 | GlaxoSmithKlineINDUSTRY | 2 | Nov 27, 2012 | clinicaltrials |
| NCT01205412 | An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain | completed | — | 552 | GlaxoSmithKlineINDUSTRY | 1 | Nov 22, 2012 | clinicaltrials |
| NCT01207999 | Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer | completed | — | 591 | GlaxoSmithKlineINDUSTRY | 3 | Nov 22, 2012 | clinicaltrials |
| NCT01213459 | Study on the Prevalence of Human Papillomavirus Types in Women >= 15 Years of Age in the Kingdom of Saudi Arabia | completed | — | 420 | GlaxoSmithKlineINDUSTRY | 1 | Nov 22, 2012 | clinicaltrials |
| NCT01702337 | Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine | completed | — | 1 | GlaxoSmithKlineINDUSTRY | 0 | Oct 8, 2012 | clinicaltrials |
| NCT00316706 | Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine | completed | Phase 3 | 1,245 | GlaxoSmithKlineINDUSTRY | 5 | Sep 18, 2012 | clinicaltrials |
| NCT01328028 | Human Papillomavirus (HPV) Type Distribution in Adult Women Diagnosed With Invasive Cervical Cancer in New Zealand | completed | — | 244 | GlaxoSmithKlineINDUSTRY | 0 | Aug 27, 2012 | clinicaltrials |
| NCT00240565 | Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma | completed | Phase 2 | 93 | GlaxoSmithKlineINDUSTRY | 1 | Aug 13, 2012 | clinicaltrials |
| NCT01158209 | An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus Types in Women in Egypt | completed | — | 490 | GlaxoSmithKlineINDUSTRY | 1 | Jul 16, 2012 | clinicaltrials |
| NCT00267488 | Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer | completed | Phase 2 | 70 | GlaxoSmithKlineINDUSTRY | 3 | Jul 11, 2012 | clinicaltrials |
| NCT00367679 | Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer | completed | Phase 2 | 35 | GlaxoSmithKlineINDUSTRY | 3 | Jun 12, 2012 | clinicaltrials |
| NCT00447226 | Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists | terminated | Phase 2 | 32 | GlaxoSmithKlineINDUSTRY | 1 | Jun 12, 2012 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials